BioMarin Pharmaceutical Inc. $BMRN Shares Sold by Gabelli Funds LLC

Gabelli Funds LLC decreased its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 41.9% in the fourth quarter, HoldingsChannel.com reports. The firm owned 17,300 shares of the biotechnology company’s stock after selling 12,500 shares during the quarter. Gabelli Funds LLC’s holdings in BioMarin Pharmaceutical were worth $1,028,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the business. North Dakota State Investment Board acquired a new position in BioMarin Pharmaceutical in the 4th quarter worth about $400,000. Abacus Wealth Partners LLC acquired a new position in BioMarin Pharmaceutical in the 4th quarter worth about $231,000. Beese Fulmer Investment Management Inc. acquired a new position in BioMarin Pharmaceutical in the 4th quarter worth about $374,000. Qsemble Capital Management LP acquired a new position in BioMarin Pharmaceutical in the 4th quarter worth about $3,393,000. Finally, DNB Asset Management AS raised its holdings in BioMarin Pharmaceutical by 6.7% in the 4th quarter. DNB Asset Management AS now owns 1,359,549 shares of the biotechnology company’s stock worth $80,798,000 after purchasing an additional 85,265 shares during the period. Institutional investors and hedge funds own 98.71% of the company’s stock.

Insider Activity at BioMarin Pharmaceutical

In related news, EVP Charles Greg Guyer sold 16,486 shares of the business’s stock in a transaction that occurred on Wednesday, March 11th. The stock was sold at an average price of $60.46, for a total transaction of $996,743.56. Following the completion of the sale, the executive vice president directly owned 79,953 shares in the company, valued at approximately $4,833,958.38. The trade was a 17.09% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Gregory R. Friberg sold 3,281 shares of the business’s stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $53.85, for a total value of $176,681.85. Following the sale, the executive vice president owned 51,818 shares of the company’s stock, valued at $2,790,399.30. The trade was a 5.95% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 26,093 shares of company stock valued at $1,555,389 over the last quarter. 0.85% of the stock is owned by company insiders.

BioMarin Pharmaceutical Stock Down 0.0%

Shares of BMRN opened at $54.09 on Friday. The company has a debt-to-equity ratio of 0.23, a quick ratio of 4.20 and a current ratio of 5.81. BioMarin Pharmaceutical Inc. has a one year low of $49.26 and a one year high of $66.28. The stock has a market capitalization of $10.45 billion, a price-to-earnings ratio of 39.48, a PEG ratio of 0.41 and a beta of 0.23. The stock has a 50 day moving average price of $54.56 and a 200 day moving average price of $56.24.

Wall Street Analyst Weigh In

BMRN has been the subject of a number of analyst reports. Royal Bank Of Canada reaffirmed a “sector perform” rating and issued a $66.00 price target on shares of BioMarin Pharmaceutical in a report on Tuesday, May 5th. Guggenheim reduced their price target on BioMarin Pharmaceutical from $106.00 to $86.00 and set a “buy” rating for the company in a report on Wednesday, February 25th. The Goldman Sachs Group began coverage on BioMarin Pharmaceutical in a report on Monday, May 11th. They issued a “neutral” rating and a $69.00 price target for the company. Weiss Ratings cut BioMarin Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, May 15th. Finally, Sanford C. Bernstein lowered their price target on BioMarin Pharmaceutical from $94.00 to $82.00 and set an “outperform” rating on the stock in a research note on Tuesday, May 5th. Two analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, BioMarin Pharmaceutical has a consensus rating of “Moderate Buy” and a consensus target price of $88.67.

Key Stories Impacting BioMarin Pharmaceutical

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: BioMarin said Voxzogo met its main goal in a late-stage hypochondroplasia study, supporting plans to file with the FDA in 2026 and boosting investor optimism about another potential growth driver. Article Title
• Positive Sentiment: Analyst commentary remained constructive overall, with Canaccord Genuity cutting its price target to $111 from $116 but reiterating a buy rating, implying substantial upside from current levels. Article Title
• Neutral Sentiment: Several press items from The Globe and Mail and TipRanks highlighted additional analyst coverage on BMRN, but they did not add a clear new operating catalyst beyond general sentiment and valuation commentary. Article Title
• Neutral Sentiment: BioMarin’s Phase 3 ENERGY 3 trial of BMN 401 met one co-primary endpoint but missed the other, making the readout mixed rather than clearly successful. Article Title
• Negative Sentiment: The mixed BMN 401 results triggered a notable selloff, with investors reacting to uncertainty around the drug’s commercial prospects and the likelihood of a clean regulatory path. Article Title

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.